Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) shot up 2.4% on Thursday . The company traded as high as $22.85 and last traded at $22.67. 19,929 shares were traded during mid-day trading, a decline of 77% from the average session volume of 87,609 shares. The stock had previously closed at $22.13.
Wall Street Analysts Forecast Growth
TVRD has been the subject of a number of recent research reports. Piper Sandler initiated coverage on shares of Tvardi Therapeutics in a research note on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Tvardi Therapeutics in a research note on Friday. They issued an "overweight" rating and a $52.00 price target for the company. Raymond James Financial initiated coverage on shares of Tvardi Therapeutics in a research note on Monday. They issued an "outperform" rating and a $62.00 price target for the company. Oppenheimer initiated coverage on shares of Tvardi Therapeutics in a research note on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price target for the company. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics to a "hold" rating in a research note on Saturday, May 24th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $64.25.
Read Our Latest Stock Report on TVRD
Tvardi Therapeutics Stock Performance
Tvardi Therapeutics Company Profile
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
See Also
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
